375 Enhanced anti-tumor activity and T-cell fitness of 2nd-generation MAGE-A1 TCR T-cells incorporating distinct CD8 co-receptor designs

• Mikhail Steklov,
• Friederike Knipping,
• Paul Najm,
• Panagiota A Sotiropoulou,
• Marleen van Loenen,
• Josephine Kemna

Affiliations

Mikhail Steklov

1T-knife Therapeutics Inc., San Francisco, CA, USA

Friederike Knipping

1T-knife Therapeutics Inc., San Francisco, CA, USA

Paul Najm

2T-knife Therapeutics Inc., Berlin, Germany

Panagiota A Sotiropoulou

1T-knife Therapeutics Inc., San Francisco, CA, USA

Marleen van Loenen

1T-knife Therapeutics Inc., San Francisco, CA, USA

Josephine Kemna

1T-knife Therapeutics Inc., San Francisco, CA, USA